Cyient DLM Q4 FY25 Earnings Analysis

- The company is executing to a confident plan with ongoing improvements across areas. - Significant opportunities are in the pipeline, including three large deals in advanced negotiation stages expected to impact revenue in the next 2 fiscal years. - Altek acquisition is expanding the footprint in North America, expected to drive higher growth due to demand for local manufacturing and political trends favoring "Made in U.S." - Aerospace and defense remain dominant sectors, but growth is also expected from industrial and medical sectors, leveraging Altek’s expertise. - Order book execution timeline varies between 9-12 months for new POs, with overall backlog spread over 18-24 months. - While short-term growth may vary due to program timing and order consumption rates, the medium to long-term outlook aims for around 30% CAGR with potential margin improvements. - FY '26 is expected to see revenue impact from current new orders and transfers ramping up progressively.

- Company aims for a consistent 10% EBITDA margin as an initial milestone with aspirations to grow beyond that (Page 12). - Margins expected to improve in Q4 and beyond due to favorable business mix and ramp down of low-margin large deals (Page 13). - EBITDA margins for Altek business are similar currently but have a roadmap to achieve about 10% sustainably (Page 9). - Operating expenses impacted by one-off costs (M&A expenses, ECL provisions) that will not repeat, leading to better operating earnings going forward (Page 13, 18). - Order book discussions indicate conversion of several large deals in the next 1-2 years, which will positively impact revenues and profits (Page 8, 18). - Organic growth expected to ease with some softness in the first half of next financial year, with stronger growth and margin expansion later (Page 13). - Overall, cautious optimism on steady revenue growth and margin improvement over coming quarters.

- The company has excess capacity currently and does not foresee a need for substantial CAPEX expansion at the moment. - Incremental CAPEX additions are planned during the year and will be communicated as funds are utilized. - About ₹190 crores of IPO proceeds are expected to be used for working capital by the end of the year, with another ₹100 crores reserved for the next financial year's working capital requirements. - 10% of the IPO proceeds were earmarked for inorganic growth, a portion of which has already been used for acquisitions, including the Altek acquisition. - Supply chain synergies are being explored to add value, including key components and distribution spend optimization.

- The company has utilized IPO proceeds for acquisitions and repaid all external borrowings, indicating no immediate new debt. - Working capital and CAPEX usage so far is lower than expected, with about ₹135 crores used, expected to reach ₹190 crores by year-end and another ₹100 crores next financial year. - There is no mention of any current plans for new fundraising via debt or equity. - The company has excess capacity and therefore no immediate need for substantial CAPEX expansion that would require new funding. - Overall, no specific current or future fundraising through debt or equity is indicated in the document.

- Consolidated order backlog stands at ₹2,142.9 crore, including ₹291.5 crore from Altek. - Standalone order backlog (excluding Altek) is approximately ₹1,850 crore. - Execution timeline for new POs varies: 9-12 months from PO to meaningful revenue; overall execution spans 18-24 months depending on client needs. - Altek has a shorter sales cycle with 50-60% visibility at the start. - Some large deals are in advanced negotiation, but specifics on deal quantum remain undisclosed; large deals expected to impact FY 2026 and beyond. - Order backlog has seen some decline due to consumption of existing large orders but a strong pipeline above $1 billion in B2B opportunities is being pursued. - No significant new client advances expected soon; free cash flow positive this quarter. - Challenges include timing shifts in awards and extended sales cycles typical of aerospace & defense sectors.